knowledge -WSS

knowledge

author：comprehensive 2025-09-30 05:30:35 Page View：13783

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： House GOP plan to stem drug shortages differs from Democrats’
Next article： Affirmative action in medical school literally saved lives

comprehensive

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

The strategy behind pharma's lawsuits over drug pricing reform

Legalexpertsunpackedthepharmaceuticalindustry'sscattershotapproachtochallengingMedicare'snewpowerton

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Why are elite athletes different? Take a look at their microbes

AdobeEliteathletesreallyaredifferentfromyouandme.Or,atleasttheirgutmicrobesare.Scientistswhoanalyzed

knowledge

leisure time

comprehensive

Why are elite athletes different? Take a look at their microbes